Blood cancer Patients' samples fuel future research
NCT ID NCT01137643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as part of this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Jul 2009
- Expected to finish
-
Jul 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Hematologic malignancies
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DISEASE CHARACTERISTICS: * Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following: * Acute myeloid leukemia * Acute lymphoblastic leukemia * Chronic myelogenous leukemia * Chronic lymphoid leukemia * Non-Hodgkin lymphoma * Hodgkin lymphoma * Myelodysplastic syndromes * Myeloproliferative disorders * Multiple myeloma * Waldenstrom macroglobulinemia * Aplastic anemia * Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage * Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599-7295, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Can adding venetoclax make donor stem cell transplants safer for High-Risk blood cancers?
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm